CLEARPOINT NEURO, INC. Financials ClearPoint Neuro, Inc.
Equities
CLPT
US18507C1036
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.26 USD | -0.94% |
|
-1.31% | -22.53% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 72.99 | 268.1 | 265.2 | 208 | 167.2 | 142.4 | - | - |
| Enterprise Value (EV) 1 | 72.99 | 268.1 | 265.2 | 208 | 167.2 | 142.4 | 142.4 | 142.4 |
| P/E ratio | -11.4 x | -37 x | -16.3 x | -12.5 x | -7.54 x | -6.95 x | -7.44 x | -8.09 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 6.51 x | 20.9 x | 16.3 x | 10.1 x | 6.98 x | 4.71 x | 3.33 x | 2.46 x |
| EV / Revenue | 6.51 x | 20.9 x | 16.3 x | 10.1 x | 6.98 x | 4.71 x | 3.33 x | 2.46 x |
| EV / EBITDA | - | -55.9 x | -23.8 x | -17.4 x | -10.6 x | -11 x | -13.6 x | -27.4 x |
| EV / FCF | - | -32.3 x | - | - | -11.6 x | -11.2 x | -21.3 x | - |
| FCF Yield | - | -3.09% | - | - | -8.64% | -8.96% | -4.69% | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 15,206 | 16,870 | 23,640 | 24,555 | 24,621 | 27,070 | - | - |
| Reference price 2 | 4.800 | 15.89 | 11.22 | 8.470 | 6.790 | 5.260 | 5.260 | 5.260 |
| Announcement Date | 20-02-12 | 21-03-04 | 22-03-01 | 23-03-01 | 24-03-12 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 11.22 | 12.83 | 16.3 | 20.55 | 23.96 | 30.26 | 42.77 | 57.8 |
| EBITDA 1 | - | -4.796 | -11.14 | -11.96 | -15.74 | -13 | -10.5 | -5.2 |
| EBIT 1 | - | -6.22 | -13.37 | -16.33 | -22.45 | -20.81 | -19.75 | -18.8 |
| Operating Margin | - | -48.48% | -82.05% | -79.47% | -93.7% | -68.76% | -46.18% | -32.53% |
| Earnings before Tax (EBT) 1 | - | -6.782 | -14.41 | -16.44 | -22.09 | -20.33 | -19.28 | -17.9 |
| Net income 1 | - | -6.782 | -14.41 | -16.44 | -22.09 | -20.33 | -19.28 | -17.9 |
| Net margin | - | -52.86% | -88.41% | -79.97% | -92.21% | -67.19% | -45.07% | -30.97% |
| EPS 2 | -0.4200 | -0.4300 | -0.6900 | -0.6800 | -0.9000 | -0.7567 | -0.7067 | -0.6500 |
| Free Cash Flow 1 | - | -8.29 | - | - | -14.44 | -12.75 | -6.678 | - |
| FCF margin | - | -64.62% | - | - | -60.27% | -42.15% | -15.61% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 20-02-12 | 21-03-04 | 22-03-01 | 23-03-01 | 24-03-12 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.574 | 4.3 | 5.031 | 5.2 | 5.146 | 5.174 | 5.433 | 5.95 | 5.762 | 6.81 | 6.994 | 7.32 | 7.691 | 8.255 |
| EBITDA 1 | -3.167 | -3.011 | -2.879 | -3.223 | -2.583 | -3.277 | -4.276 | -5.33 | -3.155 | -2.98 | -3.6 | -3.95 | -2.6 | -2.85 |
| EBIT 1 | -3.804 | -3.982 | -3.864 | -4.204 | -3.795 | -4.469 | -5.712 | -7.131 | -4.897 | -4.706 | -5.115 | -5.588 | -4.907 | -5.162 |
| Operating Margin | -83.17% | -92.6% | -76.8% | -80.85% | -73.75% | -86.37% | -105.14% | -119.85% | -84.99% | -69.1% | -73.13% | -76.34% | -63.81% | -62.53% |
| Earnings before Tax (EBT) 1 | -3.98 | -4.149 | -3.959 | -4.303 | -3.788 | -4.385 | -5.609 | -7.052 | -4.809 | -4.619 | -4.993 | -5.436 | -4.791 | -5.079 |
| Net income 1 | -3.98 | -4.149 | -3.959 | -4.303 | -3.788 | -4.385 | -5.609 | -7.052 | -4.809 | -4.619 | -4.993 | -5.436 | -4.791 | -5.079 |
| Net margin | -87.01% | -96.49% | -78.69% | -82.75% | -73.61% | -84.75% | -103.24% | -118.52% | -83.46% | -67.83% | -71.39% | -74.27% | -62.29% | -61.52% |
| EPS 2 | -0.1800 | -0.1900 | -0.1700 | -0.1800 | -0.1500 | -0.1800 | -0.2300 | -0.2900 | -0.2000 | -0.1900 | -0.1900 | -0.2033 | -0.1800 | -0.1867 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 21-11-09 | 22-03-01 | 22-05-11 | 22-08-09 | 22-11-08 | 23-03-01 | 23-05-11 | 23-08-08 | 23-11-09 | 24-03-12 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -8.29 | - | - | -14.4 | -12.8 | -6.68 | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | - | - | - | 0.72 | 0.25 | 0.25 | - |
| Capex / Sales | - | - | - | - | 2.99% | 0.84% | 0.59% | - |
| Announcement Date | 20-02-12 | 21-03-04 | 22-03-01 | 23-03-01 | 24-03-12 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
5.26
USD
Average target price
10
USD
Spread / Average Target
+90.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.53% | 142M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +0.65% | 63.06B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B |
- Stock Market
- Equities
- CLPT Stock
- Financials ClearPoint Neuro, Inc.
